Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives $5.67 Average PT from Analysts

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has earned an average rating of “Moderate Buy” from the five research firms that are currently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $5.67.

Separately, HC Wainwright decreased their price objective on shares of Karyopharm Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, March 1st.

Karyopharm Therapeutics Stock Performance

Shares of KPTI stock opened at $1.51 on Tuesday. The firm’s 50 day moving average price is $1.26 and its 200-day moving average price is $1.05. Karyopharm Therapeutics has a one year low of $0.62 and a one year high of $4.87. The firm has a market cap of $173.76 million, a P/E ratio of -1.21 and a beta of 0.01.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Thursday, February 29th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The firm had revenue of $33.75 million for the quarter, compared to analysts’ expectations of $33.50 million. During the same quarter in the prior year, the company posted ($0.43) EPS. As a group, research analysts predict that Karyopharm Therapeutics will post -1.15 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Michael Mason sold 27,687 shares of the company’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $1.17, for a total transaction of $32,393.79. Following the sale, the chief financial officer now directly owns 404,918 shares of the company’s stock, valued at approximately $473,754.06. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Karyopharm Therapeutics news, CFO Michael Mason sold 27,687 shares of the stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $1.17, for a total value of $32,393.79. Following the sale, the chief financial officer now directly owns 404,918 shares of the company’s stock, valued at approximately $473,754.06. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Richard A. Paulson sold 80,470 shares of the stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $1.17, for a total transaction of $94,149.90. Following the completion of the sale, the chief executive officer now directly owns 1,183,783 shares in the company, valued at $1,385,026.11. The disclosure for this sale can be found here. Insiders have sold a total of 165,093 shares of company stock valued at $196,952 in the last ninety days. Company insiders own 3.32% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. GSA Capital Partners LLP acquired a new stake in shares of Karyopharm Therapeutics in the third quarter worth approximately $762,000. Barclays PLC lifted its position in Karyopharm Therapeutics by 4.2% during the third quarter. Barclays PLC now owns 1,152,298 shares of the company’s stock valued at $1,544,000 after buying an additional 45,937 shares in the last quarter. Exchange Traded Concepts LLC lifted its position in Karyopharm Therapeutics by 30.2% during the third quarter. Exchange Traded Concepts LLC now owns 86,484 shares of the company’s stock valued at $116,000 after buying an additional 20,062 shares in the last quarter. BNP Paribas Arbitrage SNC lifted its position in Karyopharm Therapeutics by 24.8% during the second quarter. BNP Paribas Arbitrage SNC now owns 461,096 shares of the company’s stock valued at $825,000 after buying an additional 91,491 shares in the last quarter. Finally, Graham Capital Management L.P. acquired a new position in Karyopharm Therapeutics during the second quarter valued at approximately $112,000. 66.44% of the stock is owned by hedge funds and other institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).